Read about the latest developments in RECOVER

REMAP-CAP published results on tocilizumab and sarilumab in COVID-19 patients

On February 25, the REMAP-CAP paper: “Interleukin-6 Receptor Antagonists in Critically Ill Patients with COVID-19” was published in the New England Journal of Medicine. It shows the results of the use of tocilizumab and sarilumab in patients with severe COVID-19. Adult patients with COVID-19 who received organ support in the intensive care unit within 24 hours, were randomly assigned to receive tocilizumab, sarilumab, or standard care. The publication shows that in critically ill patients with COVID-19 receiving organ support in ICUs, treatment with the interleukin-6 receptor antagonists tocilizumab and sarilumab improved outcomes, including survival.

Read More »

RECOVER Social Science team will present at SW SAPC conference 2021

On Thursday 18 March 2021, the RECOVER Social Science team will present the results of their qualitative study at the SW SAPC on-line conference 2021. The study focuses on patients and healthcare professionals’ (HCPs) experiences of receiving and delivering care during the COVID-19 pandemic in 8 European countries.

Read More »

PRESS RELEASE: ECRAID-Base launches European Clinical Research Alliance

Following the signing of the Grant Agreement by the European Commission (EC), ECRAID-Base has secured funding of 30 million euros and will commence March 1st 2021. ECRAID-Base is the core set of activities for ECRAID (the European Clinical Research Alliance for Infectious Diseases), which aspires to become the first of its kind, pan-European clinical research network for infectious diseases in Europe. Over the five-year duration of ECRAID-Base, ECRAID will evolve into a self-sustaining, not-for-profit organisation conducting clinical research for both public and private sponsors.

Read More »

REMAP-CAP Launched its Second Video

REMAP-CAP, an Adaptive Platform Trial for Community-Acquired Pneumonia, launched its second in a series of videos. The video shows the uniqueness, smart, and easy-to-handle design of this trial. As an adaptive platform, REMAP-CAP is designed to adapt in the event of a pandemic, increasing the likelihood of patients receiving an effective treatment.

Read More »

PRESS RELEASE: Reduced mortality for sickest COVID-19 patients

Initial findings reported in November showed that tocilizumab, a drug used to treat arthritis, was likely to improve outcomes among critically ill COVID-19 patients. But the impact on patient survival and length of time on organ support in ICU was not clear at that time.
Now, the latest analysis shows that tocilizumab and a second drug called sarilumab – both types of immune modulators called IL-6 receptor antagonists – have a significant impact on patient survival, reducing mortality by 8.5%.

Read More »

The experience of European hospital-based health care workers on following infection prevention and control procedures for COVID-19

Working under pandemic conditions exposes health care workers (HCWs) to infection risk and psychological strain. Protecting the physical and psychological health of HCWs is a key priority. The Social Sciences team of RECOVER assessed the perceptions of European hospital HCWs of local infection prevention and control (IPC) procedures during the COVID-19 pandemic and the impact on their emotional wellbeing.

Read More »